PPARA and metabolic dysfunction-associated steatotic liver disease: In this study, we observed the beneficial effect of co-treatment with a PPARα agonist and metformin on the progression of NAFLD in three major manifestations of liver disease, that is, steatosis, inflammation, and fibrosis.